Tudor Investment Corp’s Novo Nordisk NVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$8.74M Sell
182,382
-258,235
-59% -$11.1M 0.01% 901
2026
Q1
$16.2M Buy
440,617
+206,349
+88% +$9.78M 0.03% 513
2025
Q4
$11.9M Buy
+234,268
New +$12M 0.02% 631
2025
Q2
Sell
-230,073
Closed -$15.6M 3609
2025
Q1
$16M Buy
230,073
+108,031
+89% +$8.92M 0.05% 279
2024
Q4
$10.5M Buy
122,042
+107,815
+758% +$11.7M 0.04% 341
2024
Q3
$1.69M Buy
+14,227
New +$1.9M 0.01% 1305
2024
Q2
Sell
-51,315
Closed -$6.8M 2647
2024
Q1
$6.59M Sell
51,315
-161,191
-76% -$19.2M 0.04% 495
2023
Q4
$22M Buy
212,506
+51,499
+32% +$5.09M 0.18% 104
2023
Q3
$14.6M Buy
161,007
+108,099
+204% +$9.52M 0.15% 115
2023
Q2
$4.28M Buy
52,908
+4,516
+9% +$369K 0.05% 501
2023
Q1
$3.85M Buy
+48,392
New +$3.43M 0.06% 484
2022
Q3
Sell
-24,012
Closed -$1.34M 2583
2022
Q2
$1.34M Buy
+24,012
New +$1.33M 0.04% 706
2022
Q1
Sell
-8,802
Closed -$493K 2465
2021
Q4
$493K Buy
+8,802
New +$477K 0.01% 1478

Other funds holding NVO

Tudor Investment Corp's NVO Position: Q2 2026 in Review

Tudor Investment Corp reduced its Novo Nordisk (NVO) stake by 59% in Q2 2026, selling an estimated $11.1M and leaving 182,382 shares worth $8.74M. The position accounts for 0.01% of the portfolio, ranked #901.

Tudor Investment Corp first reported a position in NVO in Q4 2021 and has held it in 13 quarters since. The position peaked at $22M in Q4 2023. 1,350 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

  • Tudor Investment Corp held 182,382 shares of Novo Nordisk worth $8.74M as of Q2 2026.
  • Tudor Investment Corp sold 258,235 Novo Nordisk shares in Q2 2026, an estimated $11.1M.
  • Novo Nordisk made up 0.01% of Tudor Investment Corp's portfolio in Q2 2026, its #901 holding.
  • Tudor Investment Corp first reported a position in Novo Nordisk in Q4 2021 and has held it in 13 quarters since.
  • Tudor Investment Corp's Novo Nordisk position peaked at $22M in Q4 2023.
  • 1,350 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Tudor Investment Corp's 13F filing for Q2 2026, filed 14 Aug 2026.